|
Maya's Biotech Briefing
China’s review of two Claudin 18.2 ADCs, BIO Convention takeaways on FDA language and M&A, and Racura’s first patient dosing in HARNESS-1 lead the briefing.
The top 10 stories from Thu Jun 25, 2026 07:00 AM to Fri Jun 26, 2026 07:01 AM
Generated June 26, 2026 at 7:01 AM
|
|
|
#1 Two Claudin 18.2 ADCs Enter Final Stretch Of Global Race With China NDA Published 2026-06-25 Two anti-Claudin 18.2 antibody-drug conjugates are approaching potential world-first approvals in China, with final regulatory steps underway. Covered by: insights.citeline.com |
#2 Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer Published 2026-06-25 Racura Oncology dosed the first patient in its HARNESS-1 Phase 1a/b trial evaluating RC220 with osimertinib in EGFR-mutant non-small cell lung cancer, assessing safety, pharmacokinetics, ctDNA dynamics, and early activity. Covered by: prnewswire.com |
#3 Antares gets $105M from Novartis for new cancer drugs Published 2026-06-25 Antares received $105 million from Novartis for new cancer drug development, according to Scorpion Therapeutics CEO Adam Friedman. Covered by: biopharmadive.com |
#4 Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer Published 2026-06-25 Truist Securities reports encouraging data for combination regimens of Revolution Medicines’ zoldonrasib in pancreatic ductal adenocarcinoma, citing a doubled chemotherapy response rate. Covered by: biospace.com |
#5 CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand Published 2026-06-25 CStone Pharmaceuticals appointed Arrotex to handle registration, market access, and commercialization of sugemalimab in Australia and New Zealand under an exclusive agreement. Covered by: prnewswire.com |
#6 Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy Published 2026-06-25 Fosun Pharma co-president Xinli Wang said the company used two recent deals to rapidly expand its Alzheimer’s disease portfolio and build independent U.S. capabilities. Covered by: fiercebiotech.com |
#7 AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS Published 2026-06-25 AFRRI and NIAID designed a proprietary PBI-BM2.5 protocol to evaluate Valion Bio’s entolimod for GI-ARS using validated animal models. Covered by: prnewswire.com |
#8 BIO 2026: How a gut feeling transformed cancer treatment forever Published 2026-06-25 Dr. Israel Lowy recalls early American Society of Clinical Oncology conference experiences in Chicago, where his oncology immunotherapy work was viewed skeptically by attendees. Covered by: fiercebiotech.com |
#9 Labs see rising demand for nitrosamine, topical performance and microbiome testing Published 2026-06-25 BioSpace conference discussions indicate sponsors are seeking earlier safety, quality, and performance data, driving increased demand for nitrosamine analysis, IVRT/IVPT testing, and microbiome database capabilities. Covered by: biospace.com |
#10 BIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exits Published 2026-06-25 The final day of the BIO International Convention featured discussions on US FDA-related regulatory language, Big Pharma’s role in supporting biotech events, and biotech M&A activity. Covered by: insights.citeline.com |
